You are here: Industry Insights > Arena

News List

Pfizer signs agreement to acquire Arena Pharmaceuticals for $6.7bn Pharmaceutical-Technology
December 15, 2021
Pfizer has signed a definitive agreement for the acquisition of all the outstanding shares of clinical-stage firm Arena Pharmaceuticals in a deal worth nearly $6.7bn or $100 for each share in cash.
Oravax to Present Keynote Talk on Oral COVID-19 Vaccine at the Arena International Vaccines Virtual Conference 2021 prnewswire
August 06, 2021
Oramed Pharmaceuticals Inc. today announced that its majority-owned company Oravax Medical Inc.'s oral COVID-19 vaccine will be featured in the Keynote Talk at the Arena International Vaccines Virtual Conference 2021
Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration for Development of RIST4721 for Treatment of Serious Immune-Mediated Inflammatory Diseases firstwordpharma
July 28, 2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Aristea Therapeutics, Inc. today announced a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by Aristea.
Arena Announces First Subject Dosed Etrasimod Trial for Ulcerative Colitis americanpharmaceuticalreview
September 23, 2020
Arena Pharmaceuticals announced the first subject has been dosed in the ELEVATE UC 12 global Phase 3 trial evaluating etrasimod, an investigational, next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator ...
FDA Grants Fast Track Designation for Heart Failure Treatment americanpharmaceuticalreview
January 17, 2020
Arena Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation for APD418, a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for the treatment of decompensated heart failure (DHF).
Arena Announces First Subject Dosed in Etrasimod ELEVATE UC 52 Global Phase 3 Trial americanpharmaceuticalreview
June 20, 2019
Arena Pharmaceuticals announced the first subject has been dosed in ELEVATE UC 52, the first of two pivotal trials within the Phase 3 ELEVATE UC registrational program evaluating etrasimod 2 mg in subjects with moderately to severely active ulcerative col
Arena Pharmaceuticals Reports Positive Results for Olorinab americanpharmaceuticalreview
September 27, 2018
Arena Pharmaceuticals announced positive topline results from its Phase 2a trial of olorinab, an investigational, peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of gastrointesti
Arena Pharmaceuticals Announces Board of Directors Appointment americanpharmaceuticalreview
July 11, 2018
"We are thrilled to have Kieran join our board of directors," said Tina Nova, Chairman of the Board of Directors of Arena.